Taiwan
· Delayed Price · Currency is TWD Mycenax Biotech Statistics
Total Valuation
Mycenax Biotech has a market cap or net worth of TWD 9.27 billion. The enterprise value is 9.72 billion.
| Market Cap | 9.27B |
| Enterprise Value | 9.72B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Mycenax Biotech has 206.11 million shares outstanding. The number of shares has increased by 7.60% in one year.
| Shares Outstanding | 206.11M |
| Shares Change (YoY) | +7.60% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 1.17% |
| Owned by Institutions (%) | 0.21% |
| Float | 111.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.05 |
| PB Ratio | 4.16 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -18.99 |
| EV / Sales | 16.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.10 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.54 |
| Quick Ratio | 0.94 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.72 |
| Interest Coverage | -21.04 |
Financial Efficiency
Return on equity (ROE) is -20.70% and return on invested capital (ROIC) is -9.46%.
| Return on Equity (ROE) | -20.70% |
| Return on Assets (ROA) | -8.35% |
| Return on Capital (ROIC) | -9.46% |
| Revenue Per Employee | 1.49M |
| Profits Per Employee | -1.32M |
| Employee Count | 387 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 6.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.45% in the last 52 weeks. The beta is 1.06, so Mycenax Biotech's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +22.45% |
| 50-Day Moving Average | 49.48 |
| 200-Day Moving Average | 45.31 |
| Relative Strength Index (RSI) | 35.06 |
| Average Volume (20 Days) | 703,745 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mycenax Biotech had revenue of TWD 576.98 million and -511.72 million in losses. Loss per share was -2.49.
| Revenue | 576.98M |
| Gross Profit | -316.10M |
| Operating Income | -504.29M |
| Pretax Income | -504.17M |
| Net Income | -511.72M |
| EBITDA | -243.63M |
| EBIT | -504.29M |
| Loss Per Share | -2.49 |
Balance Sheet
The company has 479.06 million in cash and 920.58 million in debt, giving a net cash position of -441.51 million or -2.14 per share.
| Cash & Cash Equivalents | 479.06M |
| Total Debt | 920.58M |
| Net Cash | -441.51M |
| Net Cash Per Share | -2.14 |
| Equity (Book Value) | 2.23B |
| Book Value Per Share | 10.82 |
| Working Capital | 347.45M |
Cash Flow
In the last 12 months, operating cash flow was -174.96 million and capital expenditures -361.78 million, giving a free cash flow of -536.73 million.
| Operating Cash Flow | -174.96M |
| Capital Expenditures | -361.78M |
| Free Cash Flow | -536.73M |
| FCF Per Share | -2.60 |
Margins
Gross margin is -54.78%, with operating and profit margins of -87.40% and -88.69%.
| Gross Margin | -54.78% |
| Operating Margin | -87.40% |
| Pretax Margin | -87.38% |
| Profit Margin | -88.69% |
| EBITDA Margin | -42.22% |
| EBIT Margin | -87.40% |
| FCF Margin | -93.02% |
Dividends & Yields
Mycenax Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.60% |
| Shareholder Yield | -7.60% |
| Earnings Yield | -5.53% |
| FCF Yield | -5.79% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mycenax Biotech has an Altman Z-Score of 3.27.
| Altman Z-Score | 3.27 |
| Piotroski F-Score | n/a |